Dr. Atkins On Long-Term Outcomes Of The Checkmate 204 Trial In Melanoma

Dr. Atkins on Long-Term Outcomes of the CheckMate 204 Trial in Melanoma

Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

10-year insights from KEYNOTE-006 and CHECKMATE 067 trials in melanoma

Melanoma & Immunotherapy: Ask Dr. Michael Atkins

MedStar Georgetown University Hospital

New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma

Managing acute and long-term side effects in checkpoint inhibitors for melanoma

CHECKMATE 205: does nivolumab improve the long-term outcomes of patients with advanced stage cHL?

Dr. Long on Nivolumab/Ipilimumab in Patients with Melanoma Brain Metastases

Dr. Hodi on Long-Term Follow-Up of Nivolumab in Patients With Melanoma

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

Dr. Spigel on Checkmate 017- Phase III Trial for Nivolumab - Sarah Cannon

Sarah Cannon Research Institute

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

Longterm Benefits from Nivolumab and Ipilimumab Combination Therapy

Specialty Pharmacy Times

Areas of unmet need for patients with melanoma

Atkins: Pembrolizumab, Ipilimumab for Melanoma, RCC

Cancer Therapy Advisor

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma